Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

PRIME

Financiado

A Personalised Living Cell Synthetic Computing Circuit for Sensing and Treating...

A Personalised Living Cell Synthetic Computing Circuit for Sensing and Treating Neurodegenerative Disorders There remain urgent and unmet needs for the treatment of neurological diseases. Epilepsy is a serious, chronic brain disease characterized by recurrent seizures. Closed-loop, implanted devices offer ways to reduce seizures in drug... ver más

31/01/2025

SOUTH EAST TECHNOL...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

SOUTH EAST TECHNOLOGICAL UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

Ver 8 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-01-19

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

FETOPEN-01-2018-2019-2020: FET-Open Challenging Current Thinking

I+D

Cerrada hace 6 años

0% 100%

8 Participantes

SOUTH EAST TECHNOLOGICAL UNI...

706.88K€ | Lider

SERVICIOS PROFESIONALES DE A...

124.14K€ | Participante

EPOS IASIS

528.80K€ | Participante

Unife

681.61K€ | Participante

Proyectos interesantes

EGNITE Engineering Graphene for developing Neural Interfaces to rev... 4M€ Cerrado

NEUROSENSE NEUROendocrine SENSor for Sudden Unexpected Death in Epileps... 4M€ Cerrado

SilVerDBS Practical design of closed loop DBS algorithms using systema... 185K€ Cerrado

RTC-2017-6225-1 Desarrollo de plataforma IoT para la eliminación selectiva d... 217K€ Cerrado

PID2019-110410RB-I00 IMPLANTE MILIMETRICO CON INTELIGENCIA ARTIFICIAL INTEGRADA P... 138K€ Cerrado

PRE2020-094293 DESARROLLO DE FARMACOS NEUROPROTECTORES CONTRA DIANAS ASTROC... 99K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 48 meses Fecha Inicio: 2021-01-19
Fecha Fin: 2025-01-31

Presupuesto del proyecto 4M€

Descripción del proyecto There remain urgent and unmet needs for the treatment of neurological diseases. Epilepsy is a serious, chronic brain disease characterized by recurrent seizures. Closed-loop, implanted devices offer ways to reduce seizures in drug-resistant patients but their efficacy is poor and they interrupt seizures only after they begin. PRIME capitalizes on a breakthrough discovery that transfer RNA (tRNA) fragments, a novel class of noncoding RNA, increase in patients in advance of when a seizure occurs. We propose to engineer human cells to respond to tRNA fragment elevations as the trigger for pre-emptive release of glial-derived neurotrophic factor (GDNF), a seizure-suppressing and disease-modifying treatment. Artificial Intelligence (AI) algorithms will be used to integrate OR or AND logic gate functions in the switching process, depending on the quantity and type of tRNA fragments and timing of their release in a given epileptic network and a second, fail-safe calcium-dependent pathway will allow GDNF release in the event of a breakthrough seizure. This enables a precise level of personalization in the design of the bio-computing cells, which will be encapsulated into a membrane device within the microenvironment scaffold, enabling the engineered cells to co-exist with natural brain tissue. Validation of the bio-computing cells will be tested in both in vitro microfluidic organ-on-a-chip as well as in vivo tests for effects on spontaneous seizures in rodents with epilepsy. PRIME’s results will provide a transformational diagnostic-therapeutic treatment for epilepsy and other neurological diseases that feature disrupted neuronal network function.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores